AstraZeneca’s long-acting coronavirus antibody combination AZD7442 has scored its first trial success, reducing the risk of developing symptomatic COVID-19 by 77% compared with placebo.
The positive results come from the PROVENT Phase III trial of the antibody combination as a pre-exposure prophylaxis – achieving...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
